RecruitingChronic Migraine
Ultrasound-guided Stellate Ganglion Block for Treatment of Chronic Migraine in Adult
Eligible age
18–65 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
To assess the 6-months effects and safety of stellate ganglion block(SGB) for Chronic Migraine (CM) patients who failure to undergo preventive therapy and are seeking a more suitable non-pharmacological therapy.
Sponsor: Beijing Tiantan Hospital
You may qualify if…
- ✓ 1. Age from 18 to 65 years;
- ✓ 2. Diagnosed with CM according to the International Classification of Headache Disorders, 3rd (ICHD-3) criteria \[Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1-211\].
- ✓ 3. not received prior prophylactic migraine treatment or, due to lack of efficacy or tolerability, had failed or had not been suitable for up to three previous prophylactic treatments from the following: Metoprolol/propranolol, amitriptyline, and flunarizine.
You may not qualify if…
- ✕ 1. BMI \<15 kg/m2 or \>35 kg/m2；
- ✕ 2. Previous SGB treatment；
- ✕ 3. History of other neurological disorders；
- ✕ 4. History of severe cardiopulmonary, hepatic or renal dysfunction；
- ✕ 5. History of allergies to any of the study drugs；
- ✕ 6. Patients with chronic use of opioids；
- ✕ 7. Preoperative coagulation abnormalities (activated partial thromboplastin time greater than 1.5 time normal value)；
- ✕ 8. Infection or mass near the puncture site；
Source: ClinicalTrials.gov · NCT06322407 · last updated 2025-01-17